Wash. molecular Dx firm targets up to $77.6M from IPO

06/14/2013 | GenomeWeb Daily News (free registration)

NanoString Technologies, which focuses on molecular diagnostics and translational life sciences systems, looks to obtain up to $77.6 million in an initial public offering. The Seattle company will use part of the proceeds to market its Prosigna Breast Cancer assay.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX